Long-term outcome of infrainguinal bypass grafting in patients with serologically proven hypercoagulability

J Vasc Surg. 2003 Feb;37(2):301-6. doi: 10.1067/mva.2003.114.

Abstract

Objective: The purpose of this study was to test the hypothesis that the long-term outcome of infrainguinal bypass grafting in patients with congenital or acquired hypercoagulability is inferior to the results in patients without documented clotting disorders.

Methods: The study was a retrospective analysis of consecutive patients from January 1994 to January 2001.

Results: Five hundred eighty-two infrainguinal bypass grafts were created in 456 patients. Indication for surgery was limb-threatening ischemia in 84%; prosthetic conduits were implanted in 38%. Seventy-four grafts were created in 57 patients with one or more serologically proven hypercoagulable states, including heparin-induced platelet aggregation (n = 37), anticardiolipin antibodies (n = 11), lupus anticoagulant (n = 8), protein C or S deficiency (n = 7), antithrombin III deficiency (n = 3), and factor V Leiden mutation (n = 1). Patients with hypercoagulability were younger (63 +/- 2 years versus 69 +/- 1 years; P =.007), more likely to have undergone prior revascularization attempts (38% versus 21%; P =.003), and more likely to have chronic anticoagulation therapy after surgery (46% versus 25%; P =.001). After 5 years (median follow-up, 19 months), patients with hypercoagulability had poorer primary patency (28% +/- 7% versus 35% +/- 5%; P =.004), primary assisted patency (37% +/- 7% versus 45% +/- 6%; P =.0001), secondary patency (41% +/- 7% versus 53% +/- 6%; P =.0001), limb salvage (55% +/- 8% versus 67% +/- 6%; P =.009), and survival (61% +/- 8% versus 74% +/- 4%; P =.02) rates. Multivariate analysis identified only prosthetic conduit choice (P =.0001), hypercoagulability (P =.0003), and limb salvage indication (P =.01) as independent predictors of graft failure.

Conclusion: Patients with serologically proven hypercoagulability have inferior long-term patency, limb salvage, and survival rates after infrainguinal bypass. The high prevalence rate (13%) of diverse hypercoagulable states in this patient population supports serologic screening, especially in referral practices.

MeSH terms

  • Aged
  • Blood Vessel Prosthesis Implantation*
  • Cohort Studies
  • Female
  • Humans
  • Inguinal Canal
  • Ischemia / blood*
  • Ischemia / mortality
  • Ischemia / surgery*
  • Leg / blood supply*
  • Leg / surgery*
  • Male
  • Middle Aged
  • Outcome Assessment, Health Care*
  • Retrospective Studies
  • Serologic Tests
  • Survival Rate
  • Thrombophilia / blood*
  • Thrombophilia / mortality
  • Thrombophilia / surgery*
  • Time Factors